cilia and flagella associated protein 92 (putative)Genealiases: FAP92 · KIAA1257
Q-omics provides the consensus-scored CFAP92 profile across patient tissues and cancer cell-line models. CFAP92 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CFAP92 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CFAP92 RNA expression shows 16,204 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, COAD, and TGCT as cancer lineages where CFAP92 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP92 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP92 survival associations across molecular data types. CFAP92 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP92 RNA expression–survival associations across cancer types. High CFAP92 expression shows unfavorable associations in BLCA, LGG, ACC, MESO, SKCM and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify BLCA as the clearest survival context for CFAP92 RNA expression.
This table summarizes CFAP92 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CFAP92. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP92 shows lower tumor expression in KICH and KIRC and higher tumor expression in COAD, BRCA, HNSC and STAD. The COAD box plot shows higher CFAP92 RNA expression in tumor versus normal tissue (log2 FC = +1.580, t-test p < 0.001).
This table shows molecular features associated with CFAP92 in patient tissues and cancer cell lines. In patient samples, CFAP92 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP92 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
